Cargando…

Short Course of Daily Prednisolone During Upper Respiratory Tract Infection for Children With Relapsing Steroid Sensitive Nephrotic Syndrome

PREDNOS 2 was a double blind placebo controlled trial done to investigate the use of daily low-dose prednisolone for the treatment of upper respiratory tract infection—related relapses. It evaluated 365 children with relapsing steroid-sensitive nephrotic syndrome with and without background immunosu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Joseph L., Bagga, Arvind, Sinha, Aditi, Sinha, Rajiv, Sankar, Janani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065233/
https://www.ncbi.nlm.nih.gov/pubmed/35410967
http://dx.doi.org/10.1007/s13312-022-2499-0
_version_ 1784699540023017472
author Mathew, Joseph L.
Bagga, Arvind
Sinha, Aditi
Sinha, Rajiv
Sankar, Janani
author_facet Mathew, Joseph L.
Bagga, Arvind
Sinha, Aditi
Sinha, Rajiv
Sankar, Janani
author_sort Mathew, Joseph L.
collection PubMed
description PREDNOS 2 was a double blind placebo controlled trial done to investigate the use of daily low-dose prednisolone for the treatment of upper respiratory tract infection—related relapses. It evaluated 365 children with relapsing steroid-sensitive nephrotic syndrome with and without background immunosuppressive treatment at 122 pediatric departments in the UK from February 1, 2013, to January 31, 2020. At the beginning of an upper respiratory tract infection, children received 6 days of prednisolone, 15 mg/m(2) daily, or matching placebo preparation. Those already taking alternate-day prednisolone rounded their daily dose using trial medication to the equivalent of 15 mg/m(2) daily or their alternate-day dose, whichever was greater. The primary outcome was the incidence of first upper respi-ratory tract infection-related relapse. The modified intention-to-treat analysis population comprised 271 children (mean (SD) age, 7.6 (3.5) years; 64.2% male), with 134 in the prednisolone arm and 137 in the placebo arm. The number of patients experiencing an upper respiratory tract infection-related relapse was 56 (42.7%) in the predniso-lone arm and 58 (44.3%) in the placebo arm (adjusted risk difference, 0.02; 95% CI, 0.14 to 0.10; P =0.70). No evidence was found that the treatment effect differed according to background immuno-suppressive treatment. A post hoc subgroup analysis assessing the primary outcome in 54 children of South Asian ethnicity (risk ratio, 0.66; 95% CI, 0.40–1.10) vs 208 children of other ethnicity (risk ratio, 1.11; 95% CI, 0.81–1.54) found no difference in efficacy of intervention in those of South Asian ethnicity (test for interaction P=0.09). The authors concluded that, results of PREDNOS 2 suggest that administering 6 days of daily low-dose prednisolone at the time of an upper respiratory tract infection does not reduce the risk of relapse of nephrotic syndrome in children in the UK and further work is needed to study the inter-ethnic differences in the study response.
format Online
Article
Text
id pubmed-9065233
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-90652332022-05-04 Short Course of Daily Prednisolone During Upper Respiratory Tract Infection for Children With Relapsing Steroid Sensitive Nephrotic Syndrome Mathew, Joseph L. Bagga, Arvind Sinha, Aditi Sinha, Rajiv Sankar, Janani Indian Pediatr Journal Club PREDNOS 2 was a double blind placebo controlled trial done to investigate the use of daily low-dose prednisolone for the treatment of upper respiratory tract infection—related relapses. It evaluated 365 children with relapsing steroid-sensitive nephrotic syndrome with and without background immunosuppressive treatment at 122 pediatric departments in the UK from February 1, 2013, to January 31, 2020. At the beginning of an upper respiratory tract infection, children received 6 days of prednisolone, 15 mg/m(2) daily, or matching placebo preparation. Those already taking alternate-day prednisolone rounded their daily dose using trial medication to the equivalent of 15 mg/m(2) daily or their alternate-day dose, whichever was greater. The primary outcome was the incidence of first upper respi-ratory tract infection-related relapse. The modified intention-to-treat analysis population comprised 271 children (mean (SD) age, 7.6 (3.5) years; 64.2% male), with 134 in the prednisolone arm and 137 in the placebo arm. The number of patients experiencing an upper respiratory tract infection-related relapse was 56 (42.7%) in the predniso-lone arm and 58 (44.3%) in the placebo arm (adjusted risk difference, 0.02; 95% CI, 0.14 to 0.10; P =0.70). No evidence was found that the treatment effect differed according to background immuno-suppressive treatment. A post hoc subgroup analysis assessing the primary outcome in 54 children of South Asian ethnicity (risk ratio, 0.66; 95% CI, 0.40–1.10) vs 208 children of other ethnicity (risk ratio, 1.11; 95% CI, 0.81–1.54) found no difference in efficacy of intervention in those of South Asian ethnicity (test for interaction P=0.09). The authors concluded that, results of PREDNOS 2 suggest that administering 6 days of daily low-dose prednisolone at the time of an upper respiratory tract infection does not reduce the risk of relapse of nephrotic syndrome in children in the UK and further work is needed to study the inter-ethnic differences in the study response. Springer India 2022-05-04 2022 /pmc/articles/PMC9065233/ /pubmed/35410967 http://dx.doi.org/10.1007/s13312-022-2499-0 Text en © Indian Academy of Pediatrics 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Journal Club
Mathew, Joseph L.
Bagga, Arvind
Sinha, Aditi
Sinha, Rajiv
Sankar, Janani
Short Course of Daily Prednisolone During Upper Respiratory Tract Infection for Children With Relapsing Steroid Sensitive Nephrotic Syndrome
title Short Course of Daily Prednisolone During Upper Respiratory Tract Infection for Children With Relapsing Steroid Sensitive Nephrotic Syndrome
title_full Short Course of Daily Prednisolone During Upper Respiratory Tract Infection for Children With Relapsing Steroid Sensitive Nephrotic Syndrome
title_fullStr Short Course of Daily Prednisolone During Upper Respiratory Tract Infection for Children With Relapsing Steroid Sensitive Nephrotic Syndrome
title_full_unstemmed Short Course of Daily Prednisolone During Upper Respiratory Tract Infection for Children With Relapsing Steroid Sensitive Nephrotic Syndrome
title_short Short Course of Daily Prednisolone During Upper Respiratory Tract Infection for Children With Relapsing Steroid Sensitive Nephrotic Syndrome
title_sort short course of daily prednisolone during upper respiratory tract infection for children with relapsing steroid sensitive nephrotic syndrome
topic Journal Club
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065233/
https://www.ncbi.nlm.nih.gov/pubmed/35410967
http://dx.doi.org/10.1007/s13312-022-2499-0
work_keys_str_mv AT mathewjosephl shortcourseofdailyprednisoloneduringupperrespiratorytractinfectionforchildrenwithrelapsingsteroidsensitivenephroticsyndrome
AT baggaarvind shortcourseofdailyprednisoloneduringupperrespiratorytractinfectionforchildrenwithrelapsingsteroidsensitivenephroticsyndrome
AT sinhaaditi shortcourseofdailyprednisoloneduringupperrespiratorytractinfectionforchildrenwithrelapsingsteroidsensitivenephroticsyndrome
AT sinharajiv shortcourseofdailyprednisoloneduringupperrespiratorytractinfectionforchildrenwithrelapsingsteroidsensitivenephroticsyndrome
AT sankarjanani shortcourseofdailyprednisoloneduringupperrespiratorytractinfectionforchildrenwithrelapsingsteroidsensitivenephroticsyndrome